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Abstract: Anaplastic (undifferentiated) thyroid carcinoma (ATC) is a rare malignancy which may
arise from transformation of a pre-existing differentiated carcinoma. We report the unique case
where a lesion of thyroid origin presented with the histological features of mature plasma cells.
Immunohistochemistry confirmed the lesion to be an anaplastic thyroid carcinoma arising from
papillary thyroid carcinoma. A tumor mimicking a malignancy of a different cellular origin can lead
clinicians to incorrect treatment approaches. Careful correlation with clinical details and knowledge
of these unique presentations is important for reaching the correct diagnosis.
Keywords: anaplastic thyroid carcinoma; plasmacytoma; mimic
1. Introduction
Anaplastic (undifferentiated) thyroid carcinoma (ATC) is a rare malignancy that accounts for
an estimated 1–2% of thyroid cancers [1]. ATCs are highly aggressive solid tumors, with a median
survival of less than 6 months after diagnosis [2–5]. They typically occur in patients who are 65 years
of age or older [1].
A large body of literature has explored the mutational landscape underlying ATCs. Through
whole-exome sequencing, one group observed that these malignancies have variations gathered within
the MAPK, Ras, and ErbB signal transduction pathways; with recurrent mutations in TP53, BRAF,
and RAS-family of genes. All the ATC lines had a combination of BRAF and TP53, or NRAS and
TP53 [6]. For anaplastic carcinomas and poorly differentiated carcinomas, activating mutations in
BRAF were exclusive to tumors arising from papillary thyroid carcinomas [7].
There is no current standardized treatment for ATC, and interventions are mostly aimed to
improve local control [8,9]. Rarely, the patient’s tumor may be meaningfully resected without extensive
spread at the time of diagnosis. These patients can undergo a multimodal curative intent treatment
consisting of surgical resection combined with chemoradiation [10]. However, most patients present
with disease that has invaded nearby structures and metastasized. Palliative intent treatment often
consists of neoadjuvant and adjuvant chemotherapy along with surgical resection to prevent airway
compromise [11]. Novel, molecular targeted therapies are used in ongoing clinical trials. These are
targeted to the mutational landscape of the tumor and include, but are not limited to, B-RAF inhibitors,
mTOR inhibitors, and multikinase inhibitors [8,12–14].
ATC is unusual compared to other thyroid malignancies in that it is typically diagnosed based on
clinical symptoms, rather than fine-needle aspiration (FNA) on a suspicious thyroid nodule. These
symptoms include rapidly enlarging neck mass, dyspnea, dysphagia, neck pain, Horner’s syndrome,
stroke, and hoarseness due to vocal cord paralysis [15].
Diagnostics 2020, 10, 29; doi:10.3390/diagnostics10010029 www.mdpi.com/journal/diagnostics
Diagnostics 2020, 10, 29 2 of 6
There are three main histological growth patterns to ATC: spindle cell, pleomorphic giant cell,
and squamoid. Most tumors demonstrate one or more of these histological patterns. Rare histological
variants also exist, such as the paucicellular variant and the rhabdoid variant. The only variant of ATC
with known prognostic significance is the paucicellular variant, which in some studies was found to
affect younger patients and have a more indolent course [16]. There are various reports in the literature
of ATC mimicking other entities such as Riedel’s thyroiditis, squamous cell carcinoma, and even
a benign histiocytic proliferation [17–19]. We present a unique variant of ATC that demonstrates
a plasmacytic morphology.
2. Case Presentation
A 54-year-old woman was referred to our tertiary care Head and Neck Surgery clinic for
evaluation of a rapidly enlarging left neck mass. She reported the neck mass had developed over the
past four months, caused mild discomfort, and had associated unintentional weight-loss. The patient
endorsed a remote 20+ year smoking history but denied any family history of head and neck
malignancies. Physical exam during this visit revealed an eight-centimeter nodal conglomerate in
the left supraclavicular area and diffusely enlarged thyroid gland with a roughly 5 cm right thyroid
mass. She had previously undergone fine needle aspiration (FNA) of the neck mass at an outside
facility which demonstrated rare degenerated atypical cells suspicious for malignancy, and a positron
emission tomography scan (PET) scan with fluorodeoxyglucose (FDG) avid lesions in the neck and
lungs concerning for metastases, which also showed tracheal deviation secondary to mass effect.
Inhouse computed tomography (CT) of her neck showed a necrotic mass, while CT angiography of
the chest showed lung lesions consistent with her previous imaging (Figure 1). Repeat FNA cytology
of the supraclavicular mass revealed a poorly differentiated carcinoma. These cells were positive for
TTF-1 and PAX8 by immunohistochemistry, and the treatment team continued to suspect a thyroid
origin. After consultation with the oncology team, the surgery team and the patient elected for surgical
resection of the left neck mass for diagnostic purposes, as well as thyroid surgery for palliation,
given the mass effect and tracheal deviation. With diagnostic surgery as the next step, additional
thyroid lesion workup such as a thyroid ultrasound, or measurement of her serologic thyroglobulin,
anti-thyroglobulin, and calcitonin were not taken at this time. The patient then underwent a left neck
dissection, and her left thyroid lobe and isthmus were resected. Additionally, the level 4 supraclavicular
mass with multiple surrounding firm, enlarged nodes was resected en bloc. The right thyroid lobe
and left central neck compartment contents were left in place to minimize surgical morbidity. The left
thyroid lobe and supraclavicular mass were sent for pathology.
Diagnostics 2020, 10, 29 3 of 6
Diagnostics 2019, 9, x FOR PEER REVIEW 2 of 6 
 
There are three main histological growth patterns to ATC: spindle cell, pleomorphic giant cell, 
and squamoid. Most tumors demonstrate one or more of these histological patterns. Rare histological 
variants also exist, such as the paucicellular variant and the rhabdoid variant. The only variant of 
ATC with known prognostic significance is the paucicellular variant, which in some studies was 
found to affect younger patients and have a more indolent course [16]. There are various reports in 
the literature of ATC mimicking other entities such as Riedel’s thyroiditis, squamous cell carcinoma, 
and even a benign histiocytic proliferation [17–19]. We present a unique variant of ATC that 
demonstrates a plasmacytic morphology. 
2. Case Presentation 
A 54-year-old woman was referred to our tertiary care Head and Neck Surgery clinic for 
evaluation of a rapidly enlarging left neck mass. She reported the neck mass had developed over the 
past four months, caused mild discomfort, and had associated unintentional weight-loss. The patient 
endorsed a remote 20+ year smoking history but denied any family history of head and neck 
malignancies. Physical exam during this visit revealed an eight-centimeter nodal conglomerate in the 
left supraclavicular area and diffusely enlarged thyroid gland with a roughly 5 cm right thyroid mass. 
She had previously undergone fine needle aspiration (FNA) of the neck mass at an outside facility 
which demonstrated rare degenerated atypical cells suspicious for malignancy, and a positron 
emission tomography scan (PET) scan with fluorodeoxyglucose (FDG) avid lesions in the neck and 
lungs concerning for metastases, which also showed tracheal deviation secondary to mass effect. 
Inhouse computed tomography (CT) of her neck showed a necrotic mass, while CT angiography of 
the chest showed lung lesions consistent with her previous imaging (Figure 1). Repeat FNA cytology 
of the supraclavicular mass revealed a poorly differentiated carcinoma. These cells were positive for 
TTF-1 and PAX8 by immunohistochemistry, and the treatment team continued to suspect a thyroid 
origin. After consultation with the oncology team, the surgery team and the patient elected for 
surgical resection of the left neck mass for diagnostic purposes, as well as thyroid surgery for 
palliation, given the mass effect and tracheal deviation. With diagnostic surgery as the next step, 
additional thyroid lesion workup such as a thyroid ultrasound, or measurement of her serologic 
thyroglobulin, anti-thyroglobulin, and calcitonin were not taken at this time. The patient then 
underwent a left neck dissection, and her left thyroid lobe and isthmus were resected. Additionally, 
the level 4 supraclavicular mass with multiple surrounding firm, enlarged nodes was resected en 
bloc. The right thyroid lobe and left central neck compartment contents were left in place to minimize 
surgical morbidity. The left thyroid lobe and supraclavicular mass were sent for pathology. 
 
Diagnostics 2019, 9, x FOR PEER REVIEW 3 of 6 
 
 
Figure 1. Computed tomography (CT) scan of the patient’s neck showing a large mass located at the 
level 4, with central cystic necrosis ((A): cross section and (B): coronal section). Axial section (C) and 
coronal section (D) taken from a CT angiogram of the chest showing metastatic lung lesions. 
The histological sections showed a dense, monotonous mass of cells with abundant amphophilic 
cytoplasm and open nuclei that contained coarse chromatin and prominent perinuclear hof. A large 
fraction of the cells was binucleated (Figure 2). This was a peculiar finding as these features are 
consistent with mature plasma cells. There were very few cells with plasmablastic or anaplastic 
features, and a distinct lack of pleomorphism or prominent nucleoli. The large lymph node that was 
taken showed the same cellular architecture, with almost complete erasure of the native lymphoid 
tissue (Figure 2). These histologic findings on the initial H&E were peculiar and further 
immunohistochemical stains verified the diagnosis. The lesion was positive for cytokeratin AE1/AE3, 
TTF-1, and PAX-8 with a markedly increased Ki-67 proliferative index at over 50%, consistent with 
an aggressive carcinoma of thyroid origin. Medullary thyroid carcinoma can have a similar cellular 
morphology, however, stains for Calcitonin were negative, which suggests against this entity. A 
negative p63 stain helped rule out a primary squamous cell carcinoma, while a negative SOX10 stain 
helped rule out a neuroendocrine or melanocytic origin. The workup for any lymphoid or histiocytic 
origin turned up negative, as the tumor cells did not stain for CD3, CD20, CD45, CD79a, CD138, or 
MUM-1. Additionally, there were areas of papillary thyroid carcinoma in both specimens collected 
(Figure 2). Further genetic testing found that the lesion contained a BRAF (V600E) mutation. With 
these findings alongside the patient’s clinical presentation, we were able to conclude that the patient 
developed an aggressive anaplastic thyroid carcinoma with a plasmacytic morphology from her 
background papillary thyroid carcinoma. The patient and family elected to undergo palliative 
radiation therapy and cytotoxic chemotherapy, as well as pursue further molecular profiling and B-
RAF inhibitor treatment in the future. 
Figure 1. Computed tomography (CT) scan of the patient’s neck showing a large mass located at the
level 4, with central cystic necrosis ((A): cross section and (B): coronal section). Axial section (C) and
coronal section (D) taken from a CT angiogra of the chest showing metastatic lung lesions.
The histological sections showed a de se, onotonous mass of cells with abu dant amphophilic
cytoplasm and open nuclei that contained chromatin and promi ent perinuclear hof. A large
fraction of the c lls was binucleated (Fig . This was a peculiar fi ding as th se f atures are
consistent with mature plasma cells. There were very few cells with plasmablastic or anaplastic features,
and a distinct lack of pleomorphism or prominent nucleoli. The large lymph node that was taken
showed the same cellular architecture, with almost complete erasure of the native lymphoid tissue
(Figure 2). These histologic findings on the initial H&E were peculiar and further immunohistochemical
stains verified the diagnosis. The lesion was positive for cytokeratin AE1/AE3, TTF-1, and PAX-8 with
a markedly increased Ki-67 proliferative index at over 50%, consistent with an aggressive carcinoma of
thyroid origin. Medullary thyroid carcinoma can have a similar cell lar morphology, however, stains
for Calcitonin were egative, which suggests against this entity. A negative p63 stain helped rule out
a primary squamous cell carcinoma, while a negative SOX10 stain helped rule out a neuroendocrine
or melanocytic origin. The workup for any lymphoid or histiocytic origin turned up negative, as the
tumor cells did not stain for CD3, CD20, CD45, CD79a, CD138, or MUM-1. Additionally, there were
areas of papillary thyroid carcinoma in both specimens collected (Figure 2). Further genetic testing
found that the lesion contained a BRAF (V600E) mutation. With these findings alongside the patient’s
clinical presentation, we were able to conclude that the patient developed an aggressive anaplastic
thyroid carcinoma with a plasmacytic morphology from her background papillary thyroid carcinoma.
The patie t and family lected to undergo palliative radiation therapy and cytotoxic chemotherapy,
as well as pursue further molecular profiling and B-RAF inhibitor treatment in the future.
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Figure 2. Histologic sections of the left thyroid lobe showing areas of papillary thyroid carcinoma (A),
H&E 400×; with a transitional morphology to microfollicular, solid sheet and plasmacytic pattern of
growth (B), H&E 40×; at a lower magnification showing sheets of plasmacytic cellularity (C), H&E
100×; and at a higher magnification showing binucleated cells with mature plasma cell features (D),
H&E 400×. Histologic sections of the supraclavicular mass showing a lymph node with metastatic
papillary thyroid carcinoma (E), H&E 40×; and a higher magnification showing a solid, undifferentiated
component (F), H&E 400×. Positive immunohistochemical staining for TTF-1, 200× (G) and PAX-8,
200× (H) on sections of the left thyroid lobe.
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3. Discussion
The diagnosis of anaplastic thyroid carcinoma is heavily clinically based, and histologic diagnosis
can be challenging and confusing. Treatment intervention and outcomes heavily differ between the
various thyroid carcinomas as well as plasma cell dyscrasias. In this case, the continued suspicion
for anaplastic thyroid carcinoma was confirmed by the immunohistochemical results and the BRAF
mutation that was found. The plasmacytoid morphology we observed is a unique histological
manifestation of ATC. While there are reports of ATC mimicking other entities, as we previously
described, this is the first case of a plasmacytoid mimicking ATC to our knowledge. This finding
did not change the diagnosis or management of the patient. However, it should be noted that many
diagnoses are made off cytology from fine needle aspiration. The paucity of cells acquired may not be
sufficient for confirmatory immunohistochemistry. The finding of these cellular features alone could
mislead clinicians to pursue a workup toward a plasma cell dyscrasia. Knowledge of these unique
presentations, as well as apt communication between pathologists and clinicians ensure patients receive
the correct treatments in these types of cases.
Author Contributions: B.Y.W. and T.T. designed the study. T.T., X.S.Z. and B.Y.W. acquired the data. J.H.M., D.T.
and B.Y.W. interpreted the data. J.H.M., D.T., B.Y.W. and X.S.Z. drafted the manuscript. J.H.M and X.S.Z. revised
the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Statement: Per the process at our institution, we do not require informed consent with no disclosure of
PHI (https://www.research.uci.edu/compliance/human-research-protections/researchers/conducting-a-case-report.
html): A HIPAA Authorization from the subject(s) of the Case Report is not required if there is access to PHI
however there is no disclosure of PHI (outside of the covered/hybrid entity) in the Case Report publication.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Nagaiah, G.; Hossain, A.; Mooney, C.J.; Parmentier, J.; Remick, S.C. Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis, and treatment. J. Oncol. 2011, 2011, 542358. [CrossRef] [PubMed]
2. Giuffrida, D.; Gharib, H. Anaplastic thyroid carcinoma: Current diagnosis and treatment. Ann. Oncol. 2000,
11, 1083–1089. [CrossRef] [PubMed]
3. Kebebew, E.; Greenspan, F.S.; Clark, O.H.; Woeber, K.A.; McMillan, A. Anaplastic thyroid carcinoma:
Treatment outcome and prognostic factors. Cancer 2005, 103, 1330–1335. [CrossRef] [PubMed]
4. Are, C.; Shaha, A.R. Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment
approaches. Ann. Surg. Oncol. 2006, 13, 453–464. [CrossRef] [PubMed]
5. Hundahl, S.A.; Fleming, I.D.; Fremgen, A.M.; Menck, H.R. A National Cancer Data Base report on 53,856
cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998, 83, 2638–2648. [CrossRef]
6. Kunstman, J.W.; Juhlin, C.C.; Goh, G.; Brown, T.C.; Stenman, A.; Healy, J.M.; Rubinstein, J.C.; Choi, M.;
Kiss, N.; Nelson-Williams, C.; et al. Characterization of the mutational landscape of anaplastic thyroid cancer
via whole-exome sequencing. Hum. Mol. Genet. 2015, 24, 2318–2329. [CrossRef] [PubMed]
7. Nikiforova, M.N.; Kimura, E.T.; Gandhi, M.; Biddinger, P.W.; Knauf, J.A.; Basolo, F.; Zhu, Z.; Giannini, R.;
Salvatore, G.; Fusco, A.; et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and
anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab.
2003, 88, 5399–5404. [CrossRef] [PubMed]
8. Cabanillas, M.E.; Zafereo, M.; Gunn, G.B.; Ferrarotto, R. Anaplastic thyroid carcinoma: Treatment in the age
of molecular targeted therapy. J. Oncol. Pract. 2016, 12, 511–518. [CrossRef] [PubMed]
9. Swaak-Kragten, A.T.; de Wilt, J.H.; Schmitz, P.I.; Bontenbal, M.; Levendag, P.C. Multimodality treatment
for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother. Oncol. 2009, 92, 100–104.
[CrossRef] [PubMed]
10. Bhatia, A.; Rao, A.; Ang, K.K.; Garden, A.S.; Morrison, W.H.; Rosenthal, D.I.; Evans, D.B.; Clayman, G.;
Sherman, S.I.; Schwartz, D.L. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
Head Neck 2010, 32, 829–836. [CrossRef] [PubMed]
Diagnostics 2020, 10, 29 6 of 6
11. Ain, K.B.; Egorin, M.J.; DeSimone, P.A.; Collaborative Anaplastic Thyroid Cancer Health Intervention
Trials (CATCHIT) Group*. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using
ninety-six-hour infusion. Thyroid 2000, 10, 587–594. [CrossRef] [PubMed]
12. Rosove, M.H.; Peddi, P.F.; Glaspy, J.A. BRAF V600E inhibition in anaplastic thyroid cancer. N. Engl. J. Med.
2013, 368, 684–685. [CrossRef] [PubMed]
13. Landa, I.; Ibrahimpasic, T.; Boucai, L.; Sinha, R.; Knauf, J.A.; Shah, R.H.; Dogan, S.; Ricarte-Filho, J.C.;
Krishnamoorthy, G.P.; Xu, B.; et al. Genomic and transcriptomic hallmarks of poorly differentiated and
anaplastic thyroid cancers. J. Clin. Investig. 2016, 126, 1052–1066. [CrossRef] [PubMed]
14. Onoda, N.; Ito, Y.; Ito, K.; Sugitani, I.; Takahashi, S.; Yamaguchi, I.; Kawakami, Y.; Tsukada, K. Phase II clinical
trial of sorafenib in Japanese patients with anaplastic thyroid carcinoma and locally advanced or metastatic
medullary thyroid carcinoma. Thyroid 2015, 25, A1202015.
15. Keutgen, X.M.; Sadowski, S.M.; Kebebew, E. Management of anaplastic thyroid cancer. Gland Surg. 2015, 4,
44–51. [PubMed]
16. Smallridge, R.C.; Ain, K.B.; Asa, S.L.; Bible, K.C.; Brierley, J.D.; Burman, K.D.; Kebebew, E.; Lee, N.Y.;
Nikiforov, Y.E.; Sara Rosenthal, M.; et al. American Thyroid Association guidelines for management of
patients with anaplastic thyroid cancer. Thyroid 2012, 22, 1104–1139. [CrossRef] [PubMed]
17. Wan, S.K.; Chan, J.K.; Tang, S.K. Paucicellular variant of anaplastic thyroid carcinoma: A mimic of Riedel’s
thyroiditis. Amer. J. Clin. Path. 1996, 105, 388–393. [CrossRef] [PubMed]
18. Veran-Taguibao, S.; Labadie, K.P.; Wang, B.Y.; Nangia, C.; Lin, H.; Lin, F. Aggressive Thyroid Carcinoma
Mimicking a Benign Histiocytic Proliferation-Utility of Tumor Markers by Immunohistochemical Analysis.
Cancer Res. Rep. 2018, 1, 1–5.
19. Oktay, M.H.; Smolkin, M.B.; Williams, M.; Cajigas, A. Metastatic anaplastic carcinoma of the thyroid
mimicking squamous cell carcinoma: Report of a case of a challenging cytologic diagnosis. Acta Cytol. 2006,
50, 201–204. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
